Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
Open accessAbstract
Although non-adherence is common across all branches of medicine, psychotic disorders pose additional challenges that increase its risk. Despite the importance of non-adherence, clinicians generally spend too little time on assessing and addressing adherence attitudes and behaviors. Importantly, how adherence is measured significantly impacts the findings, and the most frequently employed methods of asking patients or judging adherence indirectly based on efficacy or tolerability information have poor validity. Novel technologies are being developed that directly assess adherence and that can also be used to both provide real-time feedback to clinicians and serve as an intervention with patients. Several treatments are available that can positively impact adherence. Among psychosocial interventions, those combining multiple approaches and involving multiple domains seem to be most effective. Although long-acting injectable antipsychotics are theoretically a very powerful tool to assure adherence and signal non-adherence, recent results from randomized controlled trials failed to show superiority compared to oral antipsychotics. These data are in contrast to nationwide cohort studies and mirror-image studies, which arguably include more representative patients receiving long-acting antipsychotics in clinical practice. This disconnect suggests that traditional randomized controlled trials are not necessarily the best way to study interventions that are thought to work via reducing non-adherence. Clearly, non-adherence is likely to remain a major public health problem despite treatment advances. However, increasing knowledge about factors affecting adherence and leveraging novel technologies can enhance its early assessment and adequate management, particularly in patients with psychotic disorders.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patients with schizophrenia often have poor adherence to oral antipsychotics, and high relapse rates pose challenges to both patients and clinicians in the management of the disease.
“Patients with schizophrenia often have poor adherence to oral antipsychotics, and high relapse rates pose challenges to both patients and clinicians in the management of the disease [94–97].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Assertive community treatment for people with severe mental disorders
Marshall, M., & Lockwood, A. (1998) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001089 · Cited by 589 · see citing works
RetractedOsterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974 · see citing works
Adherence to Long-Term Therapies: Evidence for Action
Geest, S. D., & Sabate, E. J. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00091-4 · Cited by 6,274 · see citing works
Charles, C., Gafni, A., & Whelan, T. (1997) · Social Science & Medicine · doi:10.1016/s0277-9536(96)00221-3 · Cited by 4,137 · cited 1× · see citing works
“Most importantly, patients should be given sufficient information about the medication and be part of the decision making process (63).”
BackgroundKirk, J. M. W., MacDonald, A., Lavender, P., Dean, J. M., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,901 · see citing works
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,667 · see citing works
Shared decision making — The pinnacle of patient-centered care
Barry, M. J., & Edgman-Levitan, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1109283 · Cited by 3,433 · see citing works
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220 · see citing works
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169 · see citing works
What is Motivational Interviewing?
Rollnick, S., & Miller, W. R. (1995) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s135246580001643x · Cited by 1,737 · see citing works
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428 · see citing works
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 7× · see citing works
“Lacro et al (17) reviewed the studies published between 1980 and 2000 which identified risk factors for medication non-adherence in patients with schizophrenia.”
BackgroundInfluentialTen Things that Motivational Interviewing Is Not
Miller, W. R., & Rollnick, S. (2009) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465809005128 · Cited by 1,315 · see citing works
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088 · see citing works
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870 · see citing works
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
Buchanan, R., Kreyenbuhl, J., Kelly, D., Noel, J. M., Boggs, D., Fischer, B., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia bulletin · doi:10.1093/schbul/sbp116 · Cited by 844 · see citing works
The Role of Medication Noncompliance and Adverse Drug Reactions in Hospitalizations of the Elderly
Col, N. F. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390160093019 · Cited by 765 · see citing works
Hess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h018 · Cited by 759 · see citing works
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725 · see citing works
Psychoeducation for schizophrenia
Xia, J., Merinder, L. B., & Belgamwar, M. R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002831.pub2 · Cited by 634 · see citing works
Compliance therapy in psychotic patients: randomised controlled trial
Kemp, R., Hayward, P., Applewhaite, G., Everitt, B. J., & David, A. S. (1996) · BMJ · doi:10.1136/bmj.312.7027.345 · Cited by 633 · see citing works
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625 · see citing works
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619 · see citing works
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605 · see citing works
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603 · see citing works
Interventions to Improve Medication Adherence in Schizophrenia
Zygmunt, A., Olfson, M., Boyer, C. A., & Mechanic, D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1653 · Cited by 541 · see citing works
Randomised controlled trial of compliance therapy
Kemp, R., Kirov, G., Everitt, B. J., Hayward, P., & David, A. S. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.172.5.413 · Cited by 525 · see citing works
Intensive case management for severe mental illness
Dieterich, M., Irving, C. B., Park, B., & Marshall, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007906.pub2 · Cited by 488 · see citing works
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395 · see citing works
Self-citationMakoul, G. T., Arntson, P. H., & Schofield, T. (1995) · Social Science & Medicine · doi:10.1016/0277-9536(95)00061-b · Cited by 380 · see citing works
How often do patients with psychosis fail to adhere to treatment programmes? A systematic review
Nosè, M., Barbui, C., & Tansella, M. (2003) · Psychological Medicine · doi:10.1017/s0033291703008328 · Cited by 353 · see citing works
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N. R., Rabinowitz, J., Davidson, M., Emsley, R. A., Harvey, P. D., Kopala, L. C., McGorry, P. D., Hove, I. V., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348 · see citing works
DiBonaventura, M., Gabriel, S., Dupclay, L., Gupta, S., & Kim, E. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-20 · Cited by 333 · cited 4× · see citing works
“Schizophrenia, USA (16) 876 Naturalistic Self-report 48.”
InfluentialPatient Nonadherence To Medication in Inflammatory Bowel Disease
Sewitch, M. J., Abrahamowicz, M., Barkun, A. N., Bitton, A., Wild, G., Cohen, A., & Dobkin, P. L. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07522.x · Cited by 327 · see citing works
Lincoln, T. M., Wilhelm, K. L., & Nestoriuc, Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.022 · Cited by 317 · see citing works
Kasper, S. F., Lerman, M. N., McQuade, R. D., Saha, A. R., Carson, W. H., Ali, M. W., Archibald, D., Ingenito, G. G., Marcus, R. N., & Pigott, T. A. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309 · see citing works
Medication Adherence: A Review of the Literature and Implications for Clinical Practice
Julius, R. J., Novitsky, M. A., & Dubin, W. R. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000344917.43780.77 · Cited by 301 · see citing works
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Bilder, R. M., Hinrichsen, G. A., & Lieberman, J. A. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00312-7 · Cited by 290 · see citing works
Poor Antipsychotic Adherence Among Patients With Schizophrenia: Medication and Patient Factors
Valenstein, M. M., Blow, F. C., Copeland, L. A., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., & Stavenger, T. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007076 · Cited by 273 · see citing works
Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications
Velligan, D. I., Wang, M., Diamond, P. M., Glahn, D. C., Castillo, D., Bendle, S., Lam, Y. W. F., Ereshefsky, L., & Miller, A. L. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.9.1187 · Cited by 250 · see citing works
Antipsychotic Adherence Over Time Among Patients Receiving Treatment for Schizophrenia
Valenstein, M. M., Ganoczy, D. A., McCarthy, J. F., Kim, H. M., Lee, T. A., & Blow, F. C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1008 · Cited by 238 · see citing works
Interventions to Improve Antipsychotic Medication Adherence: Review of Recent Literature
Dolder, C. R., Lacro, J. P., Leckband, S. G., & Jeste, D. V. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085413.08426.41 · Cited by 236 · see citing works
Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment
Stilley, C. S., Sereika, S. M., Muldoon, M. F., Ryan, C. M., & Dunbar‐Jacob, J. M. (2004) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2702_6 · Cited by 223 · see citing works
Perkins, D. O., Gu, H., Weiden, P. J., McEvoy, J. P., Hamer, R. M., & Lieberman, J. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0114 · Cited by 220 · see citing works
Compliance therapy: a randomised controlled trial in schizophrenia
O’Donnell, C. P., Donohoe, G. J., Sharkey, L., Owens, N., Migone, M., Harries, R., Kinsella, A., Larkin, C., & O'Callaghan, E. (2003) · BMJ · doi:10.1136/bmj.327.7419.834 · Cited by 219 · see citing works
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L. D., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 213 · see citing works
Adherence therapy for people with schizophrenia
Gray, R. J., Leese, M., Bindman, J. P., Becker, T. M., Burti, L., David, A. S., Gournay, K., Kikkert, M., Koeter, M. W. J., Puschner, B., et al. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.019489 · Cited by 194 · see citing works
Barkhof, E., Meijer, C. J., de Sonneville, L. M. J., Linszen, D. H., & de Haan, L. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.005 · Cited by 183 · see citing works
Preventing HIV Antiretroviral Resistance through Better Monitoring of Treatment Adherence
Bangsberg, D. R. (2008) · The Journal of Infectious Diseases · doi:10.1086/533415 · Cited by 183 · see citing works
Byerly, M., Fisher, R., Whatley, K., Holland, R., Varghese, F. P., Carmody, T. J., Magouirk, B., & Rush, A. J. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.11.002 · Cited by 181 · see citing works
A Pilot Study of Barriers to Medication Adherence in Schizophrenia
Hudson, T. J., Owen, R. R., Thrush, C. R., Han, X., Pyne, J. M., Thapa, P. B., & Sullivan, G. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0211 · Cited by 173 · see citing works
Enhancement of Treatment Adherence Among Patients With Bipolar Disorder
Sajatovic, M., Davies, M. A., & Hrouda, D. R. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.3.264 · Cited by 162 · see citing works
Liu‐Seifert, H., Adams, D. H., & Kinon, B. J. (2005) · BMC Medicine · doi:10.1186/1741-7015-3-21 · Cited by 153 · see citing works
Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community?
Okuno, J., Yanagi, H., & Tomura, S. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100347 · Cited by 149 · see citing works
Clinical guideline recommendations for antipsychotic long-acting injections
Kane, J. M., & García-Ribera, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s63 · Cited by 147 · see citing works
Self-citationClinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study
Weiden, P. J., Mann, J. J., Haas, G. L., Mattson, M., & FRANCES, A. J. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1148 · Cited by 147 · see citing works
Merinder, L. B., Viuff, A. G., Laugesen, H., Clemmensen, K., Misfelt, S., & Espensen, B. (1999) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270050146 · Cited by 123 · see citing works
Medication Adherence in Outpatients With Severe Mental Disorders
Jónsdóttir, H., Opjordsmoen, S., Birkenaes, A. B., Engh, J. A., Ringen, P. A., Vaskinn, A., Aamo, T. O., Friis, S., & Andreassen, O. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d2191e · Cited by 122 · see citing works
Gäebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Eriksson, L., & Smeraldi, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.111 · Cited by 111 · see citing works
Dassa, D., Boyer, L., Benoît, M., Bourcet, S., Raymondet, P., & Bottaï, T. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2010.493503 · Cited by 111 · see citing works
Adams, C. E. (2004) · Psychiatric Bulletin · doi:10.1192/pb.28.9.351 · Cited by 83 · see citing works
Keks, N. A., Ingham, M., Khan, A., & Karcher, K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.017020 · Cited by 83 · see citing works
Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode Schizophrenia
Gäebel, W., & Riesbeck, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1116 · Cited by 82 · see citing works
Kane, J. M., Perlis, R. H., DiCarlo, L. A., Au-Yeung, K., Duong, J., & Petrides, G. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08222 · Cited by 81 · see citing works
Self-citationAn RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand
von Bormann, S. M., Robson, D., Gournay, K., & Gray, R. J. (2007) · Journal of Clinical Nursing · doi:10.1111/j.1365-2702.2007.01786.x · Cited by 78 · see citing works
How much time does it take to prescribe a new medication?
Tarn, D. M., Paterniti, D. A., Kravitz, R. L., Heritage, J. C., Liu, H., Kim, S., & Wenger, N. S. (2008) · Patient Education and Counseling · doi:10.1016/j.pec.2008.02.019 · Cited by 72 · see citing works
Medication adherence and quality of life among Nigerian outpatients with schizophrenia
Adelufosi, A. O., Adebowale, T. O., Abayomi, O., & Mosanya, J. T. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.09.001 · Cited by 65 · see citing works
Waterreus, A. J., Morgan, V. A., Castle, D. J., Galletly, C. A., Jablensky, A. V., Prinzio, P. D., & Shah, S. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412450471 · Cited by 63 · see citing works
Dosing Frequency and Adherence to Antipsychotic Medications
Pfeiffer, P. N., Ganoczy, D., & Valenstein, M. M. (2008) · Psychiatric Services · doi:10.1176/appi.ps.59.10.1207 · Cited by 42 · see citing works
A Preliminary Trial of Adherence-Coping-Education (ACE) Therapy for Early Psychosis
Uzenoff, S. R., Perkins, D. O., Hamer, R. M., Wiesen, C., & Penn, D. L. (2008) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e31817d01a5 · Cited by 32 · see citing works
Intensive Case Management for severe mental illness
Dieterich, M., Irving, C. B., & Marshall, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007906 · Cited by 32 · see citing works
Cognitive and behavioural approaches to medication adherence
Scott, J. L. (1999) · Advances in Psychiatric Treatment · doi:10.1192/apt.5.5.338 · Cited by 20 · see citing works
Schooler, N. R. (2012) · Schizophrenia Research · doi:10.1016/s0920-9964(12)70019-1 · Cited by 10 · see citing works
Davies, S., Asghar, S., Cooper, V., Lange, A., Robertson, C., Vrijens, B., & White, D. (2010) · Journal of the International AIDS Society · doi:10.1186/1758-2652-13-s4-p120 · Cited by 6 · see citing works
Kishimoto, T., Nitta, M., Borenstein, M., et al. (2012) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(12)70517-5 · Cited by 5 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 8
- Cramer JA, Roy A, Burrell A et al. Medi- cation compliance and persistence: ter- minology and definitions. Value Health 2009;11:44-7.
- Scott J. Cognitive and behavioral ap- proaches to medication adherence. Adv Psychiatr Treatment 1999;5:338-47.
- Rollnick S, Miller WR. What is motiva- tional interviewing? Behav Cogn Psy- chother 1995;23:325-34.
- Kemp R, Kirov G, Everitt B et al. Rando- mised controlled trial of compliance ther- apy: 18-month follow-up. Br J Psychiatry 1998;172:413-9.
- Gray R, Leese M, Bindman J et al. Adher- ence therapy for people with schizophre- nia. European multicentre randomised controlled trial. Br J Psychiatry 2006;189: 508-14.
- Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. Am J Psychiatry 2004;161:1-56.
- National Collaborating Centre for Men- tal Health. The NICE guidelines on core interventions in the treatment and man- agement of schizophrenia in primary and secondary care (update edition). Leices- ter, London: British Psychological Society and Royal College of Psychiatrists, 2010.
- Kishimoto T, Nitta M, Borenstein M et al. Long acting injectable vs. oral anti- psychotics in schizophrenia: a systematic review and meta-analysis of mirror- image studies. Presented at the 51st Annual Meeting of the American College of Neuropsychopharamacology, Holly- wood, December 2012. DOI 10.1002/wps.20060
Cited by
Sorted by citations
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369 · see citing works
Self-citationWhat is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324 · see citing works
Self-citationThe acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Haddad, P. M., & Correll, C. U. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318781475 · Cited by 259 · see citing works
Self-citationClinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257 · see citing works
Self-citationAntipsychotic treatment and mortality in schizophrenia.
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu164 · Cited by 208 · see citing works
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2020.2076 · Cited by 210 · see citing works
Self-citationCorrell, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205 · see citing works
Self-citationKishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186 · see citing works
Self-citationA Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works
Treatable clinical intervention targets for patients with schizophrenia
Freeman, D., Taylor, K. M., Molodynski, A., & Waite, F. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.07.016 · Cited by 125 · see citing works
Dragioti, E., Radua, J., Solmi, M., Gosling, C. J., Oliver, D., Lascialfari, F., Ahmed, M., Cortese, S., Estradé, A., Arrondo, G., et al. (2023) · World Psychiatry · doi:10.1002/wps.21068 · Cited by 130 · see citing works
Self-citationEticha, T., Teklu, A., Ali, D., Solomon, G., & Alemayehu, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120560 · Cited by 103 · see citing works
“The factors consistently associated with non-adherence in patients with schizophrenia are lack of insight, attitudes towards their illness and the medication, past experiences with their illness and its treatment, substance abuse, adverse drug reactions and lack of social support [7,9,10].”
BackgroundInfluentialDeterminants of adherence to treatment in first-episode psychosis: a comprehensive review
Leclerc, E., Noto, C., Bressan, R. A., & Brietzke, E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1539 · Cited by 78 · see citing works
Sajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44 · see citing works
Self-citationBossie, C. A., Alphs, L. D., & Correll, C. U. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000082 · Cited by 33 · see citing works
Self-citationIbrahim, W, A., Pindar, K, S., Yerima, M, M., Rabbebe, B, I., Shehu, S, et al. (2015) · Journal of Neuroscience and Behavioral Health · doi:10.5897/jnbh2015.0128 · Cited by 20 · see citing works
Widschwendter, C. G., Kemmler, G., Rettenbacher, M. A., Yalcin-Siedentopf, N., & Hofer, A. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1791-y · Cited by 18 · see citing works
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13 · see citing works
“66 Circumstances that increase the risk for nonadherence in schizophrenia are being at an earlier phase of treatment, 67,68 comorbid substance use, 69 social exclusion (i.e., homelessness), and high side effect burden.”
BackgroundMethodInfluentialZolnoori, M., Fung, K. W., Fontelo, P., Kharrazi, H., Faiola, A., Wu, Y. S. S., Stoffel, V., & Patrick, T. (2018) · JMIR Mental Health · doi:10.2196/10726 · Cited by 11 · see citing works
Intentional non-adherence to antipsychotic medication in patients with schizophrenia
Yaegashi, H., Haga, M., Misawa, F., Mizuno, Y., Suzuki, T., & Takeuchi, H. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.10.018 · Cited by 1 · see citing works
- Authors
- Kane, J. M., Kishimoto, T., & Correll, C. U.
- Affiliations
- Albert Einstein College of Medicine (US)
- Northwell Health (US)
- Venue
- World Psychiatry
- Publisher
- Wiley
- Published
- 2013-10
- Volume
- 12
- Issue
- 3
- Pages
- 216-226
- ISSN
- 1723-8617 (ISSN-L)
- PMC
- PMC3799245
- OpenAlex
- W2092173202
- Cited by
- 520
- References
- 75
- Citations by year
- 2026: 38 · 2025: 51 · 2024: 48 · 2023: 35 · 2022: 48 · 2021: 64 · 2020: 35 · 2019: 54 · 2018: 41 · 2017: 30 · 2016: 35 · 2015: 23 · 2014: 15 · 2013: 1 · 2012: 1
- FWCI
- 20.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- World Psychiatry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (P30MH090590)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacy and Medical Practices
- Keywords
- medication non-adherence, psychosis, schizophrenia, long-acting injectable antipsychotics, adherence measurement, psychosocial interventions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
